After five years of follow-up in patients with T2DM, the GLP-1 RAs and SGLT-2 inhibitors groups demonstrated significant reductions in mortality, CHD, HF, AF, stroke, peripheral vascular disease, and CKD, regardless which one of the drugs or its combination were used. The gene discussed is GCG; the disease is Stroke.